UB Paderborn / Katalog / Suche / in CDI

198P - Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix81-ix82

2012

Volltextzugriff (PDF)

Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

Gynecologic oncology, 1989-12, Vol.35 (3), p.378-382

1989

Volltextzugriff (PDF)

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

International journal of gynecology and obstetrics, 1991-02, Vol.34 (2), p.195-196

1991

Volltextzugriff (PDF)

Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian Cancer: Results of Two Prospective Randomized Trials

The New England journal of medicine, 1990-04, Vol.322 (15), p.1021-1027

1990

Volltextzugriff (PDF)

Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group

Gynecologic oncology, 2006-02, Vol.100 (2), p.349-354

2006

Volltextzugriff (PDF)

Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A gynecologic oncology group study

American journal of clinical oncology, 1986-02, Vol.9 (1), p.24-26

1986

Volltextzugriff (PDF)

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix

Obstetrics and gynecology (New York. 1953), 1977-07, Vol.50 (1), p.103

1977

Volltextzugriff (PDF)

ADRIAMYCIN-METHOTREXATE COMBINATION CHEMOTHERAPY OF ADVANCED CARCINOMA OF THE CERVIX: A Second Look

Obstetrics and gynecology (New York. 1953), 1977-01, Vol.50 (1), p.103-104

1977

Volltextzugriff (PDF)

Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study

Journal of clinical oncology, 1989-04, Vol.7 (4), p.466-470

1989

Volltextzugriff (PDF)

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

Journal of clinical oncology, 1996-07, Vol.14 (7), p.2101-2112

1996

Volltextzugriff (PDF)

Aminothiadiazole (NSC 4728) in patients with advanced cervical carcinoma: a phase II study of the gynecologic oncology group

American journal of clinical oncology, 1987-08, Vol.10 (4), p.299-301

1987

Volltextzugriff (PDF)

An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Gynecologic oncology, 1996-12, Vol.63 (3), p.304-311

1996

Volltextzugriff (PDF)

Analysis of the relationships of the ploidy and cell cycle kinetics to differentiation and the female sex steroid hormone receptors in adenocarcinoma of the endometrium

American journal of clinical pathology, 1986-05, Vol.85 (5), p.536-541

1986

Volltextzugriff (PDF)

Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women

American journal of clinical oncology, 1993-04, Vol.16 (2), p.117-122

1993

Volltextzugriff (PDF)

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

Cancer, 1996-11, Vol.78 (10), p.2193-2198

1996

Volltextzugriff (PDF)

Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (A Gynecologic Oncology Group Study)

American journal of obstetrics and gynecology, 1991-04, Vol.164 (4), p.997-1004

1991

Volltextzugriff (PDF)

Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a gynecologic oncology group study). Discussion

American journal of obstetrics and gynecology, 1991, Vol.164 (4), p.997-1004

1991

Volltextzugriff (PDF)

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

Journal of clinical oncology, 1995-07, Vol.13 (7), p.1589-1599

1995

Volltextzugriff (PDF)

Autoimmune hemolytic anemia and ovarian dermoid cysts: Case report and review of the literature

Cancer, 1981-08, Vol.48 (3), p.721-724

1981

Volltextzugriff (PDF)

Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms

American journal of obstetrics and gynecology, 1985-09, Vol.153 (2), p.124-129

1985

Volltextzugriff (PDF)

Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms: I. Quantitation of antibodies

American journal of obstetrics and gynecology, 1985-09, Vol.153 (2), p.124-129

1985

Volltextzugriff (PDF)

Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments

Cancer research (Chicago, Ill.), 1980-11, Vol.40 (11), p.4064-4069

1980

Volltextzugriff (PDF)

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix81-ix82

2012

Volltextzugriff (PDF)

Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study

Gynecologic oncology, 1999-02, Vol.72 (2), p.131-137

1999

Volltextzugriff (PDF)

CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer

American journal of clinical oncology, 1989-04, Vol.12 (2), p.106-109

1989

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

198P - Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian Cancer: Results of Two Prospective Randomized Trials

Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group

Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A gynecologic oncology group study

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix

ADRIAMYCIN-METHOTREXATE COMBINATION CHEMOTHERAPY OF ADVANCED CARCINOMA OF THE CERVIX: A Second Look

Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

Aminothiadiazole (NSC 4728) in patients with advanced cervical carcinoma: a phase II study of the gynecologic oncology group

An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Analysis of the relationships of the ploidy and cell cycle kinetics to differentiation and the female sex steroid hormone receptors in adenocarcinoma of the endometrium

Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (A Gynecologic Oncology Group Study)

Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a gynecologic oncology group study). Discussion

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

Autoimmune hemolytic anemia and ovarian dermoid cysts: Case report and review of the literature

Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms

Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms: I. Quantitation of antibodies

Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study

CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer

Suchergebnisse filtern